Undifferentiated AML cells show high levels of Bcl-2 and/or CDK2/4/6, and these mediators seem to be involved in the development of BET inhibitor resistance in undifferentiated cells; inhibition of these mediators then resensitizes cells to BET inhibitors. This evidence concerns the gene CDK2 and acute myeloid leukemia.